The Drug Development Division of Locum International focuses
on Generic Development and Innovative Generic Dosage Forms. The Beverage,
Food and Wine division is located at LocumEuro.
Partnership projects range from quite simple safe and non-allergic
pediatric syrups to innovative state-of-the-art anticancer generic drugs
(Tamoxifen Technology in UK and Ireland).
During 1981 Locum Pioneered the formulation and manufacturing
process of sugar free, color free and alcohol free paracetamol syrups
and analgesics now used all over the world by multinational pharmaceutical
firms. (Teva's and Glaxo popular pediatric analgesic liquids are 100%
The Partnership Program diversifies from large scale governmental
antibiotic production units, in as wide a field as Asmara Ethiopia (eight
different antibiotic projects commercialized) to continuing adult education
programs, conferences and workshops administered by major US Universities,
Colleges and Pharmacy Schools highlighted by LIG's annual Book Expositions
Locum International maintains a significant commitment to generic
development and timely scientific publication through it's vast journal
network. This commitment includes projects in generic dosage forms that
range from modified release tablets, soft gelatin capsules to sterile
injections and inhalation MDI / DPI aerosols.
All major dosage forms are continually being developed, with
a special hands-on emphasis on controlled and modified release solid
oral preparations and soft gelatin capsules.
Development and registration units work hand-in glove to produce
seamless technology transfers.The Group provides great tools to get
information and technology know-how fast - particularly at the members-only
section at IAGIM Center.
Every Ready-To-Go product (CMC Technical Dossier) exists in full size
industrial commercial production with Locum's world wide client base.
Technology levels exceed FDA EU and MCA current expectations.
a nutshell, Locum promotes generic drugs manufacture excellence and
high quality cost effective drug development world wide through own
research and an extensive network of partnership programs, distance
learning products and global workshops in some 23 cities and countries.
All research is made available to the pharmaceutical industry through
LIG's global publishing domain. Copyright licences for are required
for any institution utilizing Locum International databases for individual
resale such as, but not limited to libraries, universities, agents,and
legal offices and consultancies. Licenses are per country advertised
and in units of 50 users, at $10 - $15/day/country/365/50 users
Locum has developed expertise and recent research in many slow
release formulations and processing techniques suitable for commercial
products as diverse as Carbamazepine, Glipizide, Pentoxifyllin, Etodolac
and Carbidopa/Levodopa and Naproxen.
Locum conducts partnership programs (Locum-IAGIM-Bird Research
Foundations) and product know-how through the Ready-to-Go Series (CMC
Dossiers) providing a range of quality products of ongoing use to the
generic and pharmaceutical industries.
Today, Locum International combines the advantages of a flexible pharmaceutical
organization that has learnt to visualize the future with the strengths
of an established company.